



Substitute for form 1449/PTO
SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Sheet 1 of 5 Attorney Docket Number 3364.25US01

U.S. PATENT DOCUMENTS

EXAMINER INITIAL ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (<i>if known</i>)		
DK		US-2001/0002269	05-31-2001	Zhao
		US-2001/0008641	07-19-2001	Krotzer
		US-2001/0008884	07-19-2001	Worsley
		US-2001/0020007	09-06-2001	Wiss
		US-2002/0147206	10-10-2002	Howard, Jr.
		US-2002/0187958	12-12-2002	Horrobin et al.
		US-2004/0071681	04-15-2004	Muller
		US-2004/0077556	04-22-2004	Chinery
		US-2004/0081678	04-29-2004	Cincotta
		US-2004/0116351	06-17-2004	Halevie-Goldman
		US-2004/0151771	08-05-2004	Gin et al.
		US-2004/0247669	12-09-2004	Gin et al.
		US-2005/0233014	10-20-2005	Lee et al.
		US-2005/0287226	12-29-2005	Sisco et al.
		US-3,097,947	07-16-1963	Kemmerer
		US-4,237,118	12-02-1980	Howard
		US-4,397,866	08-09-1983	Wurtman
		US-5,019,594	05-28-1991	Wurtman et al.
		US-5,480,657	01-02-1996	Allen
		US-5,795,895	08-18-1998	Anchors
		US-5,977,099	1-02-1999	Nickolson
		US-6,207,699	03-27-2001	Rothman
		US-6,660,777	12-09-2003	Hinz

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)			
DK		JP10067663A2	03-10-1998	Nickolson	
EXAMINER SIGNATURE		/Daniel Kolker/ (06/12/2006)		DATE CONSIDERED	6/12/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Martin C. Hinz
				Art Unit	164 1649
				Examiner Name	Unknown
Sheet	2	of	5	Attorney Docket Number	3364.25US01
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
DK		ABELL ET AL., "Placebo Controlled Double-Blind Trial of Fluvoxamine Maleate in the Obese" <u>Journal of Psychosomatic Research</u> , 30(2): 143-146 (1986).			
↓		ACN Annual Meeting, San Juan, Puerto Rico, Dec. 15, 2000, PRNewswire (Abstract).			
↓		AGUNDEZ ET AL., "Modulation of CyPIA2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine", <u>Pharmacogenetics</u> , 8:251-258 (1998).			
		Anchors Book, "Safer Than Phen-Fen" Anchors (Ed.), page 82.			
DK		ANDREWS ET AL., "The Effects of 5-hydroxytryptophan and 5-hydroxytryptamine on Dopamine Synthesis and Release in Rat Brain Striatal Synaptosomes", <u>Journal of Neurochemistry</u> , 30:465-470 (1978).			
		AVARELLO, "Serotonin Syndrome: a reported case", <u>Neuro Sci.</u> 23:S55-S56 (2002).			
↓		BARTHOLOME ET AL., "L-dopa and 5-hydroxytryptophan Therapy in Phenylalanine-Hydroxylase Activity", <u>The Lancet</u> 2 (Nov. 22): 1042-1043 (1975).			
		BAUMANN ET AL., "Transport Mechanisms for the Antidepressant Citalopram in Brain Microvessel Endothelium", <u>Brain Res.</u> 831(1-2); 229-36 (1999) (Abstract).			
		BOUCHARD ET AL., "Citalopram and Viloxazine in the treatment of depression by means of slow drop infusion A double-linked Comparative Trial", <u>Journal of Affective Disorders</u> 46:51-58 (1997).			
		COPPEN ET AL. "Levodopa and L-tryptophan Therapy in Parkinsonism", <u>The Lancet</u> , March 25, 1972.			
		Drug Facts and Comparison 1999 Edition, Riley (ed).			
		DUNNER ET AL., "Affective Disorder: Studies with Amine Precursors", <u>Am J. Psychiatry</u> 132(2): 180-183 (1975).			
↓		FAVA, "Weight Gain and Antidepressants", <u>J. Clin Psychiatry</u> , 61 (Suppl 11 (1-2):37-41 (2000)(Abstract).			
EXAMINER SIGNATURE	/Daniel Kolker/ (06/12/2006)			DATE CONSIDERED	06/12/2006
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</p>					

Substitute for form 1449/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Martin C. Hinz
				Art Unit	1614 1649
				Examiner Name	Unknown
Sheet	3	of	5	Attorney Docket Number	
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	<p>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published</p>			^{T²}
DK		FAVA ET AL., "Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment", <u>J. Clin. Psychiatry</u> , 61(11): 863-7 (2000) (Abstract).			
		FOGLIA ET AL., "Plasma levels of citalopram enantiomers and metabolites in elderly patients", <u>Psychopharmacol Bull</u> , 33(1):109-12 (1997) (Abstract).			
		GELENBERG ET AL., "Tyrosine for the treatment of depression", <u>Nutr. Health</u> , 3(3):163-73 (1984).			
		HARVEY ET AL., "Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors", <u>Clin Neuropharmacol</u> , 23(2):90-7 (Mar-Apr 2000) Abstract.			
		HURLEY ET AL., "Pyrrolo [1,4] benzodiazepine Antibiotics. Biosynthesis of the Antitumor Antibiotic 11-Demethyltumaymycin and its Biologically Inactive metabolite Oxotumaymycin to Streptomyces achromogene", <u>Biochemistry</u> , 15(17):3760-3769 (1976).			
		KRAMARCY ET AL., "Effects of Drug-Induced Changes in Brain Monoamines on Aggression and Motor Behavior in Mice", <u>European Journal of Pharmacology</u> , 99:141-151 (1984).			
		LEINONEN ET AL., "Efficacy and tolerability of mirtazapine versus citalopram: a double-blind randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group", <u>Int. Clin Psychopharmacol</u> , 14(6):329-37 (1999) (Abstract).			
		LI KAM WA ET AL., "Renal metabolism and effects of the glutamyl derivates of L-dopa and 5-dydroxytryptophan in man", <u>Clinical Science</u> , 91:177-185 (1996).			
		LINDSTROM, "Aromatic-L-Amino-Acid Decarboxylase Activity in Mouse Pancreatic Islets", <u>Biochimica et Biophysica Acta</u> , 884:276-281 (1986).			
▼		LINDSTROM, ET AL., "Aromatic amino acids and pancreatic islet function: a comparison of L-tryptophan and L-5-hydroxytryptophan", <u>Molecular and Cellular Endocrinology</u> , 48:121-126 (1986).			
EXAMINER SIGNATURE		/Daniel Kolker/ (06/12/2006)		DATE CONSIDERED	06/12/2006
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p>					
<p><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Martin C. Hinz
				Art Unit	1614-1649
				Examiner Name	Unknown
Sheet	4	of	5	Attorney Docket Number	
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
DK		SCHLOSBERG ET AL., "Effects of L-Dopa and L-5-Hydroxytryptophan on Locomotor Activity of the Rat after Selective or combined destruction of Central Catecholamine and Serotonin Neurons", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 211(2):296-304 (1979).			
		SHINTAKU ET AL., "Diagnosis and treatment of 6-pyruvoyl-tetrahydropterin synthase deficiency", <u>Brain & Development</u> , 22:S118-S121 (2000).			
		STERNBERG ET AL, "Development of Scleroderma-like Illness during Therapy with L-5-hydroxytryptophan and Carbidopa", <u>The New England Journal of Medicine</u> , 303(14):782-787 (1980).			
		TANAKA ET AL., "Hyperphenylalaninemia Due to Impaired Dihydrobiopterin Biosynthesis", <u>Eur. J. Pediatr.</u> , 136:275-280 (1981).			
		THURMOND ET AL, "Effects of Dietary Tyrosine, Phenylalanine, and Tryptophan on Aggression in Mice", <u>Pharmacology Biochemistry & Behavior</u> , 6:475-478 (1977).			
		TRULSON ET AL., "Behavioral Effects of Serotonergic and Dopaminergic Drugs in Cats Following Chronic Amphetamine Administration", <u>European Journal of Pharmacology</u> , 99:313-324 (1984).			
		WEITBRECHT ET AL., "Der Einfluss von l-Tryptophan auf die L-Dopa-Resportion", <u>Dtsch Med Wochenschr</u> , 101(1): 20-22 (1976).			
		Neuroscience Litigation Pleadings			
▼		Dave Peterson Affidavit (April 11, 2005)			
EXAMINER SIGNATURE		/Daniel Kolker/ (06/12/2006)		DATE CONSIDERED	06/12/2006
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p>					
<i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i>					

Substitute for form 1449/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Martin C. Hinz
				Art Unit	1614-1640
				Examiner Name	Unknown
Sheet	5	of	5	Attorney Docket Number	3364.25US01
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
DK		MALONE ET AL., "Treatment (Rx) of 76 Patients with Primary Fibromyalgia (1° FM) with Combined Dopaminergic and Serotonergic Drugs", Arthritis & Rhuematism, 39:S92 (1992) (Abstract).			
		MAREK ET AL., "A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action", Psychopharmacology 109:2-11 (1992).			
		MATHIAU ET AL, "Absence of Serotonergic Innervation from Raphe Nucleus in Rat Cerebral Blood Vessels - II. Lack of Tryptophan Hydroxylase Activity In Vitro" Neuroscience, 52(3): 657-665 (1993).			
		The Medical Letter, "Fluoxetine (prozac) and Other Drugs for Treatment of Obesity" Abranowics et al (Ed.) NOVEMBER 25 1994			
.		The Merck Index, Budavari et al., (Ed.) 11TH EDITION 1989, P. 355-356 AND 361-362			
.		MEYERS, "Use of Neurotransmitter Precursors for Treatment of Depression", Alternative Medicine Review, 5(1):64-71 (2000).			
		MOON, "The Effects of Psychomotor Performance of Fluvoxamine Versus Mianserin in Depressed Patients in General Practice", BJCP, 45(4): 259-262 (1991).			
		NIEDENS ET AL, "First fungal aromatic L-amino acid decarboxylase from a paclitaxel-producing Penicillium raistrickii", Mycologia, 91(4):61-26 (1999) (Abstract).			
		RABEY ET AL., "L-tryptophan Administration in L-Dopa-Induced Hallucinations in Elderly Parkinsonian Patients" Gerontology, 23:438-444 (1977).			
▼		SAWAKI ET AL., "Some correlations between Procaine-Induced Convulsions and Monamines in the Spinal Cord of Rats", Japan, J. Pharmacol, 51:369-376 (1989).			
EXAMINER SIGNATURE	/Daniel Kolker/ (06/12/2006)		DATE CONSIDERED	06/12/2006	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p>					
<i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i>					



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
is not subject to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/785,158
				Filing Date	2/23/2004
				First Named Inventor	HINZ
				Art Unit	1649
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	HINZ101USA

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Daniel Kolker/ (06/12/2006)	Date Considered	06/12/2006
-----------------------	------------------------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031
GSA GEN. REG. NO. 27, PART II, ITEM 20, FORM 1

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
is required to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/785,158
		Filing Date	02/23/2004
		First Named Inventor	Hinz
		Art Unit	<u>1614</u> /b49
		Examiner Name	
Sheet	1	of	1
		Attorney Docket Number	HINZ101USA

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Daniel Kolker/ (06/12/2006)	Date Considered	06/12/2006
--------------------	------------------------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE & STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Hinz
				Art Unit	1617 → 1649
				Examiner Name	
Sheet 1 of 1				Attorney Docket Number	3364.25US01
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Number-Kind Code ² (<i>if known</i>)			
DK		US-4,377,595	03-22-1983	Wurtman	
✓		US-5,189,064	02-23-1993	Blum et al.	
		US-5,939,076	08-17-1999	Allocca	
		US-			
FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	³
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)			
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			²
DK		VAN PRAAG, "In Search of the Mode of Action of Antidepressants – 5-HTP/Tyrosine Mixtures in Depressions", Neuropharmacology, 22(3B):433-440 (1983).			
EXAMINER SIGNATURE	/Daniel Kolker/ (06/12/2006)			DATE CONSIDERED	06/12/2006
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>					
<small>¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.</small>					
<small>This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</small>					

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<p style="text-align: center;">O I P E INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p> <p style="text-align: right;">AN 13 2006</p> <p style="text-align: left;">PATENT AND TRADEMARK OFFICE</p>				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Hinz
				Art Unit	1649
				Examiner Name	Unknown
1	of	1	Attorney Docket Number	3364.25US01	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Number-Kind Code ² (<i>if known</i>)			
DK		US-6,132,724	10-17-2000	Blum	
DK		US-2002/0025972	02-28-2002	Hinz	
		US-			
FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ <i>(if known)</i>			
DK		WO 01/26642	04-19-2001	Bechthold et al.	
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
DK		COPPEN ET AL., "Levodopa and L-Tryptophan Therapy in Parkinsonism" <i>The Lancet</i> , 299(7752): 654-658, 1972 (Abstract).			
EXAMINER SIGNATURE		/Daniel Kolker/ (06/12/2006)		DATE CONSIDERED	06/12/2006
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>					
<small>¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.</small>					
<small>This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</small>					

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Hinz
				Art Unit	1614-1649
				Examiner Name	Kolker, D.
SHEET	1	of	1	Attorney Docket Number	3364.25US01
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Number-Kind Code ² (<i>if known</i>)			
DK		US-5,527,788	06-18-1996	Svec et al.	
		US-09/523,114	03-10-2000	Hinz	
		US-6,323,236	11-27-2001	McElroy	
		US-2002/0040054	04-04-2002	Hinz	
		US-2003/0181509	09-25-2003	Hinz	
		US-2004/0101575	05-27-2004	Hinz	
		US-2005/0065190	05-24-2005	Hinz	
		US-2005/0233008	10-20-2005	Hinz	
		US-11/282,965	11-18-2005	Hinz	
		US-11/353,644	02-14-2006	Hinz	
		US-11/353,643	02-14-2006	Hinz	
		US-			
FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)			
DK		EP0347066	12-20-1989	Boegesoe et al.	
DK		GB2137493	10-10-1984	Mathur	
EXAMINER SIGNATURE		/Daniel Kolker/ (06/12/2006)	DATE CONSIDERED	06/12/2006	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p>					

